To date, immunization has consisted of two principle pathways: (1) replication of infective agent; (2) enhancement of immune function. Given the lack of Success of the two current pathways, the current researcher (author) has conceptualised (developed) the new, or third, pathway of site attachment inhibition. The methodology surrounding site attachment inhibition therapeutics has been discussed in previous lectures (Reference Citations 1-9). It involves both medication based treatment of established infections and preventative immunization (new generation; stem cell therapy based). New generation immunization involves stem cell therapy (including mutagenesis and knockout) of particular genetic targets such to achieve immunity (resistance) to infectious agents that is similar to what occurs with hereditary genetic variations/mutations).
The methodology for identifying genetic targets has been discussed in previous lectures. In brief, “Using methodology relating to CRISPR, CRISPR Cas 9 and related technologies would allow comparison between cells in which entry of the pathogen is occurring to those in which entry of the pathogen is not occurring (or, not able to) and through analysis of the genetics of the human cellular biology used by the pathogen to gain cellular attachment (or, transfer and entry), the genes to be targeted in mutagenesis and knockout can be analysed. The pathogen machinery also is to be analysed.”From the above, it is clear that the current research has directed a methodology that encourages ascertainment of the genetic targets by way of first principles as opposed to direct copying. Direct copying may be considered a more ownership type attitude toward the genetics of humans and other species.